The buccal minor salivary glands as starting point for a metastasizing adenocarcinoma – report of a case
© Ettl et al; licensee BioMed Central Ltd. 2008
Received: 17 May 2008
Accepted: 30 July 2008
Published: 30 July 2008
With the 2005 WHO classification of salivary gland tumours and its increasingly recognized diagnostic entities, the frequency of adenocarcinoma (NOS) has decreased significantly.
This paper describes a fast growing adenocarcinoma (NOS), originating from the minor salivary glands of the left buccal mucosa with a rapid onset of multiple local and distant metastases, especially in the lung. A lung primary was unlikely as the tumour was characterized by positivity for cytokeratin 20 and negativity for the thyroid transcription factor-1 protein (TTF-1) in immunohistochemistry.
A rare case of an adenocarcinoma (NOS) of the minor salivary glands with a rapid development and an unfavourable clinical course is reported. It shows that additional immunohistochemical analysis can decisively contribute to determine the site of the primary tumour in cases with unknown primary.
Epithelial tumours arising in the intra-oral minor salivary glands account for 9–23% of all salivary gland tumours [1, 2] and of these, carcinomas are responsible for about 40–54% [3–5]. Adenocarcinoma not otherwise specified (NOS) is a malignant neoplasm of the salivary glands with ductal, glandular or secretory differentiation that cannot be attributed to any other currently recognized type of salivary gland carcinoma [6, 7]. With the 2005 WHO classification of salivary gland tumours and its increasingly recognized diagnostic entities, frequency of adenocarcinoma (NOS) has decreased significantly . This article describes a fast growing adenocarcinoma (NOS), originating in the left buccal mucosa with a rapid onset of multiple local and distant metastases. Immunohistochemistry was found to be useful in confirming a salivary gland origin.
A 68-year old female patient with a painless swelling of the left buccal mucosa was referred to our department. An initial incisional biopsy of the lesion was inconclusive and magnetic resonance imaging (MRI) of the head and neck diagnosed a benign appearing connective tissue tumour, arising without local invasion.
Detailed medical history pointed to a more than three months consisting, rapidly enlarging mass in the patient's left buccal mucosa, which provoked pain while using her dentures. The patient further complained of lack of appetite, sleeping disturbance and weight loss of 11 kilograms (15% of body weight) over the last five months. Tobacco and alcohol abuse was excluded.
Due to the extent of the disease, palliative chemotherapy was initiated.
Data concerning the relative frequency of adenocarcinoma (NOS) vary from 1.2% to 17.8% of all salivary gland carcinomas [6, 8], since in previous classifications tumours, which are currently established as more specific histologies like salivary duct carcinoma, epithelial-myoepithelial carcinoma or polymorphous low-grade adenocarcinoma, were often categorized as adenocarcinoma (NOS) [6, 8]. About 40% of adenocarcinomas (NOS) are located in the minor salivary glands , with a relative frequency of 4.3%–10.3% of all minor gland carcinomas [3–5]. The palate is the most commonly involved site (39%–75%), followed by the lips and the buccal mucosa, as described in the case report [3, 4]. In most cases, the lesion presents as a firm, solid and painless mass, which may be characterized by ulceration and fixation to the surrounding soft tissues. Mechanical irritation like friction from the patient's denture may evoke tenderness.
In general there are various differential diagnoses for a buccal swelling comprising both benign and malignant neoplasia. Tumours may originate from the squamous epithelium (papilloma, squamous cell carcinoma), the soft tissue (fibromatosis, nodular fasciitis, malignant fibrous histiocytoma, fibrosarcoma, leiomyoma, leiomyosarcoma, lipoma, liposarcoma, neurofibroma, schwannoma, malignant peripheral nerve sheath tumour, hemangioma, angiosarcoma) and from salivary glands (pleomorphic adenoma, adenoid cystic carcinoma etc.) [9, 10]. In view of the fact that the majority of Non-Hodgkin's lymphomas affecting the oral cavity present as a submucosal mass, this differential diagnosis should also be taken into account, although the hard palate and the gingiva are the most common intraoral sites of occurrence . Oral metastatic lesions can also be the initial appearance of undiagnosed primary malignancies. Because of the rapid growth of the tumour, its firm appearance and spread to adjacent structures, its intraoperatively obvious bony invasion and considering the patient's history (lack of appetite and weight loss), a malignancy was the most likely diagnosis in the present case.
Microscopically, adenocarcinoma (NOS) is characterized by a variable spectrum of different architectural patterns, which may include glandular, papillary, cystic, cribriform or solid structures . Tumours with considerable heterogeneity of growth patterns, which cannot clearly be attributed to well known entities of adenocarcinoma should best be classified as adenocarcinomas (NOS). According to the most recent WHO classification, tumours showing a high morphologic heterogeneity, a low mitotic rate and slight nuclear atypia can better be assessed as polymorphous low-grade adenocarcinoma. Hence, the majority of adenocarcinomas will be of high malignancy grade, as in this case, characterized by hyperchromatic and pleomorphic nuclei, necrosis and high mitotic rate . Adenocarcinomas with overt presence of ductal structures should better be classified as salivary duct carcinoma (SDC) than as adenocarcinoma NOS, but the distinction might be arbitrary. Immunohistochemistry may help, as more than 90% of SDCs are specifically positive for androgen receptors (AR) and because most of these carcinomas show positive staining for HER-2/neu (c-erbB-2) .
Cytokeratins (CK) are distinctive intermediate filaments, which are confined to epithelia and indicate the tissue of origin in malignant transformation and metastasis . They may also be useful in the determination of the primary site. While CK 5/6 is common in squamous epithelia, the expression of CK 7 and CK 20 is distinctive in glandular epithelia. This may include tumours like colorectal, pancreatic or bronchioloalveolar adenocarcinoma as well as adenocarcinomas of the salivary glands . Since the patient in this case report presented with an additional adenocarcinoma of the lung, the primary site of the carcinoma had to be elucidated, especially oral metastasis by a lung primary had to be excluded. The thyroid transcription factor 1 (TTF-1) is a specific marker of the thyroid gland and the epithelia of the lung, regulating the expression of surfactant in the latter organ [14, 15]. Evidence of antibodies to TTF-1 may identify the lung as the primary site of origin in adenocarcinoma with unknown primary. In the reported case TTF-1 turned out to be negative. Together with the positivity for CK20 which is usually negative in primary adenocarcinomas of the lung, a salivary gland origin was most likely. Immunohistochemistry might also aid in the differential diagnosis of salivary gland carcinoma types. In the present case the tumour cells were negative for CK5/6, a marker of basal cells, myoepithelial cells and squamous epithelium excluding a variety of carcinoma types: mucoepidermoid carcinoma, squamous cell carcinoma and myoepithelial carcinoma.
The overall prognosis of adenocarcinoma (NOS) depends on clinical stage and malignancy grade. For stage I a 10-year survival rate of 75% has been reported by Spiro et al , dropping to 36% for stage II, irrespective of grade. According to the same study 15-year survival rates for low-, intermediate- and high-grade adenocarcinoma are 54%, 31% and 3% respectively . However, this study most likely includes tumours, which are today, further subclassified. Tumour site has also been mentioned to govern the prognosis. Carcinomas of the oral cavity are reported to have a more favourable outcome (76% at 10 years) than those of the parotid (26% at 10 years) or the submandibular glands . In a study of 54 patients with adenocarcinoma (NOS) of the major and minor salivary glands, cervical lymph node metastases were recorded in 23% of the patients and distant metastases developed in 37% of these patients .
Although incidence of the adenocarcinoma (NOS) is decreasing with the establishment of new neoplastic entities of the salivary glands, this carcinoma still occurs and should be taken into account in case of intraoral mucosal tumours with indiscernible borders. High-grade malignancies arising in the minor glands may show a rapid growth and early metastases to lymph nodes and distant organs. Additional immunohistochemical analysis can decisively contribute to determine the site of the primary tumour.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-In-Chief of this journal.
- Auclair PL, Ellis GL: Adenocarcinoma, not otherwise specified. Surgical pathology of the salivary glands. Edited by: Ellis GL, Auclair PL, Gnepp DR. 1991, Philadelphia: Saunders, 318-332.
- Eveson JW, Cawson RA: Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol. 1985, 146: 51-58. 10.1002/path.1711460106.View ArticlePubMed
- Buchner A, Merrell PW, Carpenter WM: Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. J Oral Pathol Med. 2007, 36: 207-214.View ArticlePubMed
- Wang D, Li Y, He H, Liu L, Wu L, He Z: Intraoral minor salivary gland tumors in a Chinese population: a retrospective study on 737 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007, 104: 94-100. 10.1016/j.tripleo.2006.07.012.View ArticlePubMed
- Yih W-Y, Kratochvil FJ, Stewart JCB: Intraoral minor salivary gland neoplasms: Review of 213 cases. Oral Maxillofac Surg. 2005, 63: 805-810. 10.1016/j.joms.2005.02.021.View Article
- Li J, Wang BY, Nelson M, Li L, Hu Y, Urken ML, Brandwein-Gensler M: Salivary adenocarcinoma, not otherwise specified. Arch Pathol Lab Med. 2004, 128: 1385-94.PubMed
- Auclair P, Wal Van der JE: Salivary Glands: Adenocarcinoma NOS. World Health Organization Classification of Tumours. Pathology and Genetics of the Head and Neck Tumours. Edited by: Barnes L, Eveson JW, Reichart P, Sidransky D. 2005, Lyon: IARC, 238-239.
- Batsakis JG, El-Naggar AK, Luna MA: "Adenocarcinoma, not otherwise specified": A diminishing group of salivary carcinomas. Ann Otol Rhinol Laryngol. 1992, 101: 102-104.View ArticlePubMed
- Philipsen HP: Benign soft tissue tumors of the oral cavity. DZZ. 2001, 56: 11-5.
- Ramani P, Chandrasekar T, Anuja N, Muthusekar R, Sherlin HJ, Kulkarni A: A swelling in the buccal mucosa with intracranial involvement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007, 103: 308-13. 10.1016/j.tripleo.2006.09.010.View ArticlePubMed
- Di Palma S, Simpson RHW, Skalova A, Leivo I: Major and minor salivary glands. Salivary duct carcinoma. Pathology of the head and neck. Edited by: Cardesa A, Slootweg PJ. 2006, Berlin Heidelberg New York: Springer, 154-155.
- Chu P, Wu E, Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000, 13: 962-72. 10.1038/modpathol.3880175.View ArticlePubMed
- Meer S, Altini M: CK7+/CK20 – immunoexpression profile is typical of salivary gland neoplasia. Histopathology. 2007, 51: 26-32. 10.1111/j.1365-2559.2007.02728.x.View ArticlePubMed
- Chang YL, Lee YC, Liao WY, Wu CT: The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer. 2004, 44: 149-57. 10.1016/j.lungcan.2003.10.008.View ArticlePubMed
- Chhieng DC, Cangiarella JF, Zakowski MF, Goswami S, Cohen J-M, Yee HT: Use of thyroid transcription factor 1, PE-10, and Cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer. 2001, 93 (5): 330-6. 10.1002/cncr.9048.View ArticlePubMed
- Spiro RH, Huvos AG, Strong EW: Adenocarcinoma of salivary origin: Clinicopathologic study of 204 patients. Am J Surg. 1982, 144: 423-31. 10.1016/0002-9610(82)90416-0.View ArticlePubMed
- Matsuba HM, Mauney M, Simpson JR, Thawley SE, Pikul FJ: Adenocarcinomas of major and minor salivary gland origin: A histopathologic review of treatment failure patterns. Laryngoscope. 1988, 98: 784-8.PubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.